The jump in arrests and transfers to ICE custody resulted in a seven-fold increase in arrests of people with no convictions, ...
A partial government shutdown would likely have little impact on immigration enforcement operations, since ICE and CBP got ...
Everyday Health on MSN
How to plan for successful home SCIg self-administration for primary immunodeficiency
Learn how to self-administer SCIg at home for primary immunodeficiency. Tips on preparation, reducing pain, managing ...
The capital infusion will help USA Rare Earth advance its plan for a magnet manufacturing plant and a mine at a rare earth ...
Intellia Therapeutics said on Tuesday that the U.S. drug regulator has lifted a clinical hold on one of its late-stage gene therapy trials, allowing the company to resume testing its experimental drug ...
The vote comes amid fury over the Trump administration’s aggressive ICE crackdown on American cities and a pair of fatal ...
ClearPoint Neuro is positioned for robust growth in 2026, driven by IRRAS, the PRISM 1.5T system clearance, and the company's new CRO facility. While the immediate future of uniQure's AMT-130 remains ...
TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the upcoming schedule of presentations highlighting BRIUMVI ® (ublituximab-xiiy), to be presented (ACTRIMS) annual forum, being held February 5 – ...
Current and former officials describe growing frustration and disillusionment with the Trump administration’s approach, even ...
The FDA has accepted for review the sBLA for subcutaneous lecanemab-irmb as a weekly starting dose for Alzheimer disease.
GlobalData on MSN
FDA to review Eisai’s Leqembi Iqlik sBLA for Alzheimer’s
The FDA has set a Prescription Drug User Fee Act action date for 24 May 2026.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results